No Data
No Data
Jasper Therapeutics Analyst Ratings
JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70
BTIG Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $90
Stifel Maintains Jasper Therapeutics(JSPR.US) With Buy Rating
Buy Rating on Jasper Therapeutics Focused on Briquilimab's Efficacy With Reduced Toxicity
Capital One Financial Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $55